Healthcare platform NADclinic has appointed general practitioner Dr Tony Banerjee, founder and CEO of healthcare platform HarleyDoc, as its Global Chief Medical Officer (GCMO).
The appointment follows a strategic partnership between the two platforms, building on their previous collaboration on Superhumxn+, a medically governed peak performance and longevity initiative.
Under the partnership, NADclinic will integrate HarleyDoc’s clinical leadership, governance frameworks and global medical escalation pathways across its UK and international operations.
The company adds that Dr Banerjee’s appointment strengthens clinical oversight, regulatory readiness and medical accountability as NADclinic continues to expand.
As part of the agreement, HarleyDoc will act as NADclinic’s global clinical infrastructure and escalation partner, while NADclinic retains responsibility for longevity protocols, diagnostics, IV therapies and performance programmes.
The companies share that the partnership reflects a broader shift away from trend-led wellness towards clinically governed, outcomes-driven healthcare.
Iain De Havilland, founder and CEO of NADclinic, commented, “Our ambition has always been to scale longevity and performance globally without compromising on safety, integrity or science. Partnering with HarleyDoc and appointing Dr Banerjee as our GCMO brings an unparalleled level of clinical governance, international assurance and leadership. This marks a defining moment in NADclinic’s evolution.”
Dr Banerjee, founder and CEO of HarleyDoc and GCMO of NADclinic, adds, “Longevity is at a crossroads. This partnership represents a return to medicine – to structure, accountability and data-led care. Through Superhuman+, we saw what was possible when governance and optimisation work together. Now, we are building something far bigger: a future-ready, globally scalable model for longevity that is safe, intelligent and medically led.”